Research programme: cystic fibrosis transmembrane conductance regulator modulators - Vertex Pharmaceuticals
Alternative Names: C-18; CF-106951; CFcor-325; VRT-325; VRT-534Latest Information Update: 30 Oct 2021
At a glance
- Originator Vertex Pharmaceuticals
- Class Piperazines; Quinazolines; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis